Halozyme Therapeutics Inc. diskutieren
Halozyme Therapeutics Inc.
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
36,53 €
1,81 %
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at Morgan Stanley from $65.00 to $64.00. They now have an "overweight" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is now covered by analysts at Berenberg Bank. They set a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at Morgan Stanley from $60.00 to $61.00. They now have an "overweight" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at HC Wainwright from $61.00 to $60.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at HC Wainwright from $60.00 to $61.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at Morgan Stanley from $61.00 to $59.00. They now have an "overweight" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at HC Wainwright from $61.00 to $48.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at HC Wainwright from $48.00 to $50.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Neueste Beiträge
Loop_Capital in Crown Holdings Inc. diskutieren